Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

By Rene Pretorius

April 21, 2025

Summary

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a Phase 3 trial. It showed significant efficacy, lowering A1C levels by 1.3% to 1.6% and achieving weight loss of up to 16 pounds. The drug’s safety profile matched injectable GLP-1 medications, with common gastrointestinal side effects. Orforglipron is the first oral small molecule GLP-1 receptor agonist to finish Phase 3, offering a convenient option for type 2 diabetes and obesity.

Key Insights

  • Efficacy: Orforglipron reduced A1C levels and induced weight loss. Over 65% of participants on the highest dose achieved an A1C below 6.5%.
  • Safety Profile: The drug’s safety was similar to injectable GLP-1 therapies, with mild to moderate gastrointestinal side effects.
  • Innovation: As a small molecule, orforglipron may be easier to produce and scale up than peptide-based GLP-1 agonists.

The Oral GLP-1 Medication Market

Type 2 diabetes may affect 760 million adults by 2050, increasing demand for effective treatments. GLP-1 receptor agonists help with glucose control and weight management, but most require injections, which can reduce compliance. Oral GLP-1 medication like orforglipron could improve adherence. The World Health Organization supports innovative treatments for chronic diseases, aligning with Lilly’s mission.

Implications

Orforglipron’s Phase 3 success has key implications:

  • Accessibility and Cost: A once-daily pill could lower costs and improve adherence compared to injectables.
  • Market Impact: Projected sales of $11.8 billion by 2030 could boost the GLP-1RA market.
  • Healthcare Implications: Innovative treatments may improve chronic disease management, reducing long-term costs and enhancing quality of life.

For more details, visit here.

Reference url

Recent Posts

Antimicrobial Resistance Art: Bridging Science and Health Through Visual Storytelling

By João L. Carapinha

April 9, 2026

Antimicrobial resistance art is powerfully demonstrated in the illustrated album Sketching Antimicrobial Resistance: Thirty Stories, One Health, published in November 2025 by the EU-JAMRAI 2 initiative. The publication brings together 30 original artworks from artists across 30 European ...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007

By João L. Carapinha

April 7, 2026

New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total ...
Impact of Insulin Copay Caps on Medicare Beneficiary Health and Spending

By João L. Carapinha

In this update, we highlight a JAMA Internal Medicine article that analyzed the real-world impact of insulin copay caps on Medicare beneficiaries with type 2 diabetes. According to a new study, these policies have successfully lowered out-of-pocket insulin costs and improved adherence among exist...